CN101687860B - 用于治疗疼痛的n-(8-杂芳基四氢萘-2-基)或n-(5-杂芳基色满-3-基)甲酰胺衍生物 - Google Patents
用于治疗疼痛的n-(8-杂芳基四氢萘-2-基)或n-(5-杂芳基色满-3-基)甲酰胺衍生物 Download PDFInfo
- Publication number
- CN101687860B CN101687860B CN2008800215491A CN200880021549A CN101687860B CN 101687860 B CN101687860 B CN 101687860B CN 2008800215491 A CN2008800215491 A CN 2008800215491A CN 200880021549 A CN200880021549 A CN 200880021549A CN 101687860 B CN101687860 B CN 101687860B
- Authority
- CN
- China
- Prior art keywords
- amine
- chromene
- dihydro
- acid
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(NC(C*1)Cc2c1cccc2*)=O Chemical compound *C(NC(C*1)Cc2c1cccc2*)=O 0.000 description 2
- JPPBAXDOHHKXDR-UHFFFAOYSA-N C(c1ccccc1)N(Cc1ccccc1)C(C1)COc2c1c(-c1ncccc1)ccc2 Chemical compound C(c1ccccc1)N(Cc1ccccc1)C(C1)COc2c1c(-c1ncccc1)ccc2 JPPBAXDOHHKXDR-UHFFFAOYSA-N 0.000 description 1
- ZPIKTLNAGWBHAO-SANMLTNESA-N C(c1ccccc1)N(Cc1ccccc1)[C@@H](C1)COc2c1c(-c(cc1)c[n]3c1ncc3)ccc2 Chemical compound C(c1ccccc1)N(Cc1ccccc1)[C@@H](C1)COc2c1c(-c(cc1)c[n]3c1ncc3)ccc2 ZPIKTLNAGWBHAO-SANMLTNESA-N 0.000 description 1
- SFXMBMZOULZIPR-UHFFFAOYSA-N CC(C)CCNC(c(cc1)ncc1C(O)=O)=C Chemical compound CC(C)CCNC(c(cc1)ncc1C(O)=O)=C SFXMBMZOULZIPR-UHFFFAOYSA-N 0.000 description 1
- IGGUZPKESUQARQ-UHFFFAOYSA-N CC(C)COc(nc1)ccc1C(O)=O Chemical compound CC(C)COc(nc1)ccc1C(O)=O IGGUZPKESUQARQ-UHFFFAOYSA-N 0.000 description 1
- TXBFRHXJLLIECK-AREMUKBSSA-N CC1(C)OB(c2cccc(CC3)c2C[C@@H]3N(Cc2ccccc2)Cc2ccccc2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(CC3)c2C[C@@H]3N(Cc2ccccc2)Cc2ccccc2)OC1(C)C TXBFRHXJLLIECK-AREMUKBSSA-N 0.000 description 1
- PYLLESPRRWTUGF-UHFFFAOYSA-N CCCCS(c(cc1)ncc1C(OC)=O)(=O)=O Chemical compound CCCCS(c(cc1)ncc1C(OC)=O)(=O)=O PYLLESPRRWTUGF-UHFFFAOYSA-N 0.000 description 1
- GITXURLGHCBMCI-UHFFFAOYSA-N CCCN(CCC)C(c(cc1)ncc1C(O)=O)=O Chemical compound CCCN(CCC)C(c(cc1)ncc1C(O)=O)=O GITXURLGHCBMCI-UHFFFAOYSA-N 0.000 description 1
- FOYGUVNXMHHDJU-QHCPKHFHSA-N COc(nn1)cc(-c2cccc(OC3)c2C[C@@H]3N(Cc2ccccc2)Cc2ccccc2)c1OC Chemical compound COc(nn1)cc(-c2cccc(OC3)c2C[C@@H]3N(Cc2ccccc2)Cc2ccccc2)c1OC FOYGUVNXMHHDJU-QHCPKHFHSA-N 0.000 description 1
- HMRPCMARRCJKEF-UHFFFAOYSA-N C[n]1c(COc(nc2)ccc2C(O)=O)ncc1 Chemical compound C[n]1c(COc(nc2)ccc2C(O)=O)ncc1 HMRPCMARRCJKEF-UHFFFAOYSA-N 0.000 description 1
- DNRZSZVHDQMRPV-AREMUKBSSA-N Cc([nH]nc1C)c1-c1c(C[C@@H](CC2)N(Cc3ccccc3)Cc3ccccc3)c2ccc1 Chemical compound Cc([nH]nc1C)c1-c1c(C[C@@H](CC2)N(Cc3ccccc3)Cc3ccccc3)c2ccc1 DNRZSZVHDQMRPV-AREMUKBSSA-N 0.000 description 1
- PFCBHSCUDXCGPH-LBPRGKRZSA-N Cc(cc1)ncc1-c1cccc(OC2)c1C[C@@H]2N Chemical compound Cc(cc1)ncc1-c1cccc(OC2)c1C[C@@H]2N PFCBHSCUDXCGPH-LBPRGKRZSA-N 0.000 description 1
- IIKVOTZOAYSYPE-UHFFFAOYSA-N Cc(nc1)ncc1-c1cccc(OC2)c1CC2=N Chemical compound Cc(nc1)ncc1-c1cccc(OC2)c1CC2=N IIKVOTZOAYSYPE-UHFFFAOYSA-N 0.000 description 1
- RFSVCDHDQBJMCF-VWLOTQADSA-N Cc(nc1)ncc1-c1cccc(OC2)c1C[C@@H]2N(Cc1ccccc1)Cc1ccccc1 Chemical compound Cc(nc1)ncc1-c1cccc(OC2)c1C[C@@H]2N(Cc1ccccc1)Cc1ccccc1 RFSVCDHDQBJMCF-VWLOTQADSA-N 0.000 description 1
- VDRQHMGBTQMKRR-UHFFFAOYSA-N NC(C1)COc2c1c(-c1cncnc1)ccc2 Chemical compound NC(C1)COc2c1c(-c1cncnc1)ccc2 VDRQHMGBTQMKRR-UHFFFAOYSA-N 0.000 description 1
- SAOXLDWNBROTAQ-JTQLQIEISA-N N[C@@H](C1)COc2c1c(-c1cc(F)ncc1)ccc2 Chemical compound N[C@@H](C1)COc2c1c(-c1cc(F)ncc1)ccc2 SAOXLDWNBROTAQ-JTQLQIEISA-N 0.000 description 1
- GXFSLVZKUACELA-NSHDSACASA-N N[C@@H](C1)COc2c1c(-c1ccc(CO)nc1)ccc2 Chemical compound N[C@@H](C1)COc2c1c(-c1ccc(CO)nc1)ccc2 GXFSLVZKUACELA-NSHDSACASA-N 0.000 description 1
- GOVSOQLVHHGISJ-NSHDSACASA-N N[C@@H](C1)COc2c1c(-c1cnccc1)ccc2 Chemical compound N[C@@H](C1)COc2c1c(-c1cnccc1)ccc2 GOVSOQLVHHGISJ-NSHDSACASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91331207P | 2007-04-23 | 2007-04-23 | |
| US60/913,312 | 2007-04-23 | ||
| PCT/SE2008/050459 WO2008130320A2 (en) | 2007-04-23 | 2008-04-22 | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101687860A CN101687860A (zh) | 2010-03-31 |
| CN101687860B true CN101687860B (zh) | 2012-07-04 |
Family
ID=39876087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800215491A Expired - Fee Related CN101687860B (zh) | 2007-04-23 | 2008-04-22 | 用于治疗疼痛的n-(8-杂芳基四氢萘-2-基)或n-(5-杂芳基色满-3-基)甲酰胺衍生物 |
Country Status (23)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| EP3091021B1 (en) * | 2009-10-26 | 2019-08-28 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| EP2532656A1 (en) | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| WO2012027289A1 (en) | 2010-08-23 | 2012-03-01 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| WO2012039657A1 (en) * | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102603659B (zh) * | 2012-03-01 | 2014-03-26 | 雅本化学股份有限公司 | 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法 |
| TWI631105B (zh) * | 2013-01-31 | 2018-08-01 | 維泰克斯製藥公司 | 作爲鈉通道調節劑之喹啉及喹噁啉醯胺 |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| CA2938719A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| MA43231B1 (fr) | 2015-11-13 | 2020-08-31 | Dae Woong Pharma | Bloqueur des canaux sodiques |
| CN105541774B (zh) * | 2016-01-13 | 2018-06-15 | 华中师范大学 | 3,4-二氢香豆素类化合物及其制备方法和用途 |
| DK3615527T3 (da) * | 2017-06-30 | 2024-05-06 | Elanco Animal Health Gmbh | Nye azaquinolin-derivater |
| ES2986630T3 (es) | 2018-01-19 | 2024-11-12 | Cytokinetics Inc | Dihidrobenzofuranos y análogos del indeno como inhibidores del sarcómero cardíaco |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| US12187712B2 (en) | 2018-06-26 | 2025-01-07 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7467349B2 (ja) | 2018-09-10 | 2024-04-15 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
| EP3972963A1 (en) | 2019-05-21 | 2022-03-30 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904361D0 (sv) * | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
| WO1994012493A1 (en) * | 1992-11-25 | 1994-06-09 | Sandoz, Ltd. | 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals |
| JPH0827153A (ja) * | 1994-07-12 | 1996-01-30 | Nippon Kayaku Co Ltd | アザクロマン誘導体及びその用途 |
| SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| GB9713804D0 (en) * | 1997-06-30 | 1997-09-03 | Novo Nordisk As | Particulate polymeric materials and their use |
| JPH1135569A (ja) | 1997-07-22 | 1999-02-09 | Meiji Milk Prod Co Ltd | ポリフェノール化合物及びこれを含有する医薬 |
| SE9702799D0 (sv) * | 1997-07-25 | 1997-07-25 | Astra Ab | New compounds |
| SE9703377D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| SE9703378D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
| NZ579370A (en) | 2003-08-08 | 2011-06-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| WO2006119451A1 (en) * | 2005-05-04 | 2006-11-09 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| WO2008008020A1 (en) * | 2006-07-12 | 2008-01-17 | Astrazeneca Ab | 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
| SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
-
2008
- 2008-04-21 SA SA8290245A patent/SA08290245B1/ar unknown
- 2008-04-22 MX MX2009011364A patent/MX2009011364A/es active IP Right Grant
- 2008-04-22 CA CA002685141A patent/CA2685141A1/en not_active Abandoned
- 2008-04-22 RU RU2009138137/04A patent/RU2460730C2/ru not_active IP Right Cessation
- 2008-04-22 NZ NZ581353A patent/NZ581353A/en not_active IP Right Cessation
- 2008-04-22 WO PCT/SE2008/050459 patent/WO2008130320A2/en active Application Filing
- 2008-04-22 US US12/596,878 patent/US8143408B2/en not_active Expired - Fee Related
- 2008-04-22 CN CN2008800215491A patent/CN101687860B/zh not_active Expired - Fee Related
- 2008-04-22 MY MYPI20094419A patent/MY146662A/en unknown
- 2008-04-22 JP JP2010506133A patent/JP2010525056A/ja active Pending
- 2008-04-22 BR BRPI0810354-2A2A patent/BRPI0810354A2/pt not_active IP Right Cessation
- 2008-04-22 AU AU2008241610A patent/AU2008241610B2/en not_active Ceased
- 2008-04-22 KR KR1020097022164A patent/KR20100015827A/ko not_active Withdrawn
- 2008-04-22 EP EP08779260A patent/EP2158198B1/en active Active
- 2008-04-23 UY UY31046A patent/UY31046A1/es not_active Application Discontinuation
- 2008-04-23 PE PE2008000697A patent/PE20090727A1/es not_active Application Discontinuation
- 2008-04-23 CL CL2008001170A patent/CL2008001170A1/es unknown
- 2008-04-23 TW TW097114910A patent/TW200848037A/zh unknown
- 2008-04-23 AR ARP080101710A patent/AR066266A1/es not_active Application Discontinuation
-
2009
- 2009-10-01 IL IL201309A patent/IL201309A0/en unknown
- 2009-10-13 ZA ZA200907137A patent/ZA200907137B/xx unknown
- 2009-10-29 EC EC2009009706A patent/ECSP099706A/es unknown
- 2009-10-29 CO CO09122476A patent/CO6251361A2/es not_active Application Discontinuation
-
2012
- 2012-03-23 US US13/427,981 patent/US20120238579A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2158198A4 (en) | 2012-01-04 |
| RU2009138137A (ru) | 2011-05-27 |
| KR20100015827A (ko) | 2010-02-12 |
| SA08290245B1 (ar) | 2012-02-12 |
| IL201309A0 (en) | 2010-05-31 |
| WO2008130320A2 (en) | 2008-10-30 |
| RU2460730C2 (ru) | 2012-09-10 |
| NZ581353A (en) | 2012-02-24 |
| JP2010525056A (ja) | 2010-07-22 |
| CA2685141A1 (en) | 2008-10-30 |
| PE20090727A1 (es) | 2009-07-23 |
| US20100137322A1 (en) | 2010-06-03 |
| US20120238579A1 (en) | 2012-09-20 |
| MX2009011364A (es) | 2009-11-05 |
| TW200848037A (en) | 2008-12-16 |
| EP2158198A2 (en) | 2010-03-03 |
| ZA200907137B (en) | 2010-07-28 |
| AU2008241610A1 (en) | 2008-10-30 |
| US8143408B2 (en) | 2012-03-27 |
| ECSP099706A (es) | 2009-11-30 |
| MY146662A (en) | 2012-09-14 |
| AU2008241610B2 (en) | 2011-08-18 |
| AR066266A1 (es) | 2009-08-05 |
| CN101687860A (zh) | 2010-03-31 |
| EP2158198B1 (en) | 2013-03-20 |
| CO6251361A2 (es) | 2011-02-21 |
| CL2008001170A1 (es) | 2009-05-22 |
| BRPI0810354A2 (pt) | 2014-10-21 |
| UY31046A1 (es) | 2008-11-28 |
| WO2008130320A3 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101687860B (zh) | 用于治疗疼痛的n-(8-杂芳基四氢萘-2-基)或n-(5-杂芳基色满-3-基)甲酰胺衍生物 | |
| JP6388991B2 (ja) | キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド | |
| EP3661923B1 (en) | N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders | |
| JP6904970B2 (ja) | Ｂ型肝炎抗ウイルス剤 | |
| CA3175436A1 (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| CN104334546B (zh) | 作为激酶抑制剂的新的环‑取代的n‑吡啶基酰胺 | |
| CN111491623A (zh) | 化合物以及它们在治疗癌症中的用途 | |
| KR101670126B1 (ko) | 신규 프탈라지논 유도체 및 그 제조방법 | |
| BR112016020621B1 (pt) | Composto, composição farmacêutica, inibidor de atividade da enzima ezh1 e/ou ezh2, agente terapêutico para tumores, e, agente antitumor | |
| CN103781776A (zh) | 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物 | |
| KR20200083970A (ko) | B형 간염 항바이러스제 | |
| CZ53194A3 (en) | 0-heteroaryl-, 0-alkylheteroaryl-, 0-alkenylheteroaryl- and 0-alkinylheteroaryl macrolide compounds, process of their preparation and pharmaceutical preparations in which they are comprised | |
| WO2023232135A1 (zh) | Pde4b抑制剂及其用途 | |
| TW202409046A (zh) | 氧雜氮雜環庚三烯衍生物 | |
| CN102046618A (zh) | 羟基喹喔啉甲酰胺衍生物 | |
| US10160745B2 (en) | Piperidine and azepine derivatives as prokineticin receptor modulators | |
| WO2021218997A1 (zh) | 取代的氮杂五元环类化合物及其在药物中的应用 | |
| TW202346304A (zh) | 囊腫纖維化跨膜傳導調節蛋白之調節劑 | |
| WO2021218992A1 (zh) | 取代的吡咯烷类化合物及其在药物中的应用 | |
| EP4495111A1 (en) | Novel compound and use thereof for inhibiting checkpoint kinase 2 | |
| HK40020739A (en) | N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders | |
| HK40020739B (en) | N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders | |
| NZ746955B2 (en) | Hepatitis b antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20130422 |